Evan Darwin BA, Jessica Cervantes BA, and Hadar Lev-Tov MD
University of Miami Miller School of Medicine, Miami, FL
is then allowed to sit with the medication in clinic for 15 to 30 minutes. After this short incubation, clinical response is typically evident as a lighter patch in the area of application. We do not need to wait for a full response, as the goal of this test is not to determine which medication the patient will have the greater response with, but rather whether or not the patient will have any response to either medication. The patient can then decide if they are happy with the response and a relevant prescription is offered. Treatment of the erythema associated with rosacea is largely directed at quality of life improvement and this pearl targets this goal by saving patients time and money as they can potentially avoid an ineffective medication and get an idea of what their skin will look like treated. Furthermore, in our anecdotal experience this test leads to improved adherence and patient satisfaction as the patients are aware of their own response to the treatments.
The authors have no conflicts of interest to report.
Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1):e1361574.
Del Rosso JQ. Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now? J Clin Aesthet Dermatol. 2017;10(7):28-32.
Harper J, Del Rosso JQ, Ferrusi IL. Cross-Sectional Survey of the Burden of Illness of Rosacea by Erythema Severity. J Drugs Dermatol. 2018;17(2):150-158.
Hoover RM, Erramouspe J. Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea. Ann Pharmacother. 2018;52(3):263-267.
Baumann L, Goldberg DJ, Stein Gold L, et al. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial. J Drugs Dermatol. 2018;17(3):290-298.
Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633-641.
Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018.
Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11):1369-1371.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.